Home
 /
Papers
 /
Neuroscience
 /
A genetically defined injured C-fibre nociceptor associated with neuromas drives chronic spontaneous neuropathic pain
Preprint
Open access
V1
Top 1% · Validated by QED

A genetically defined injured C-fibre nociceptor associated with neuromas drives chronic spontaneous neuropathic pain

Xiangsunze Zeng, Rosa I. Martinez-Garcia, Shamsuddin A. Bhuiyan +21 more
February 2026
 ·
bioRxiv
 ·
DOI 
10.1101/2025.09.30.679489
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Neuroscience this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By identifying injured SSTR2+ C-nociceptors as the cellular driver of spontaneous neuroma pain—mechanistically separate from evoked allodynia—this work overturns a longstanding conflation of neuropathic pain subtypes and opens a precise, cell-type-specific therapeutic target.

QED claims analysis

Summary

Chronic spontaneous neuropathic pain arising from peripheral nerve injury is driven by ectopic activity of injured axons from a genetically-defined C-fiber nociceptor subtype (SSTR2+ neurons) within neuromas, establishing a cellular and mechanistic separation from stimulus-evoked neuropathic pain mediated by intact larger-diameter sensory neurons in spared nerves.

See full analysis
Main Claim 1 –

Delayed post-injury limb flicks indicate spontaneous paroxysmal pain

Supporting evidence

  • 24-hour monitoring stabilizes limb flick measurement and reveals circadian modulation
Main Claim 2 –

Neuroma-originating activity drives chronic spontaneous pain behaviors

Supporting evidence

  • Neuroma-driven spontaneous pain is independent of Piezo2 mechanotransduction
Main Claim 3 –

Small-diameter DRG neurons generate spontaneous neuroma pain signals

Main Claim 4 –

Distinct peripheral drivers mediate spontaneous versus evoked neuropathic pain

Abstract

Spontaneous pain is a common but poorly understood consequence of peripheral nerve injury, including injuries that lead to the formation of neuromas. We developed a chronic neuroma model for measuring spontaneous pain-related behaviours in mice, which revealed that limb flicks - emerging predominantly 2 months post-injury - reflect spontaneous paroxysmal pain. Ectopic activity of injured dorsal root ganglia (DRG) sensory neurons whose axonal endings terminate within the neuroma drives this spontaneous pain. In vivo imaging showed that a subset of small-diameter DRG sensory neurons are the source of spontaneous neural signals emanating from the neuroma, and these spontaneously active neurons are distinct from the intact larger diameter sensory neurons that mediate stimulus-evoked mechanical allodynia from spared nerves. Cell-type–specific gain- and loss-of-function studies identified a genetically- and functionally-defined subtype of small-diameter C-fibre nociceptors whose injured axons in neuromas drive spontaneous limb flicks/neuropathic pain. These findings establish the neurobiological basis of spontaneous pain enabling targeted pain management strategies and define a cellular and mechanistic separation between spontaneous and evoked neuropathic pain.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?